What's Happening?
The Biosimilars Forum, led by executive director Julie Reed, is advocating for a legislative fix to the Inflation Reduction Act (IRA) concerning Medicare price negotiations for brand biologics. The proposed
Biosimilars Access and Affordability Act aims to clarify and streamline rules for delaying price negotiations when a biosimilar competitor is nearing market entry. Currently, the IRA includes a special rule allowing for two one-year delays for brand biologics if a biosimilar is being developed and expected to launch within that timeframe. However, the implementation details, left to the Centers for Medicare & Medicaid Services (CMS), have created confusion, particularly with CMS's introduction of a 'bona fide marketing' term that Reed describes as subjective and vague. This ambiguity led to instances like Stelara being selected for price negotiation despite imminent biosimilar competition, which launched with significant discounts.
Why It's Important?
This legislative effort is crucial for the U.S. healthcare market as it seeks to enhance competition and reduce drug costs. The Biosimilars Forum argues that competition from biosimilars is more effective in driving down prices than direct price negotiation. For example, Stelara biosimilars launched with 85% to 95% discounts, while Medicare's negotiated price for Stelara was only a 60% discount a year later. By providing certainty for biosimilar developers regarding negotiation delays, the proposed act aims to encourage investment and development in the biosimilar industry. This stability is essential for ensuring a robust pipeline of lower-cost medicines, ultimately benefiting Medicare beneficiaries through increased access and reduced out-of-pocket expenses. The current ambiguities in the IRA's implementation risk undermining the potential cost savings that biosimilar competition can offer.
What's Next?
Bills supporting the Biosimilars Access and Affordability Act have been introduced in both the House of Representatives and the Senate, enjoying bipartisan support. The Biosimilars Forum is actively working to advance this legislation, emphasizing its importance for the long-term sustainability of the biosimilar industry. If passed, the act would codify an automatic two-year delay for brand biologics facing biosimilar competition, provided the biosimilar launches by the end of that period. This would require biosimilar developers to certify their launch date to CMS and ensure all intellectual property barriers are removed. The Forum acknowledges that while passage this year is uncertain, they will continue to advocate for the bill in subsequent legislative sessions, highlighting its role in making biosimilars more accessible and affordable for patients.
Beyond the Headlines
The debate over Medicare price negotiation and biosimilar competition highlights a broader tension in U.S. pharmaceutical policy: balancing innovation incentives for brand-name drugs with the need for affordable access to medicines. The Biosimilars Forum's argument that 'competition works better than negotiation' suggests a market-based approach to cost reduction, contrasting with direct government intervention. This legislative push could set a precedent for how future drug pricing policies are shaped, potentially shifting focus towards fostering competitive markets rather than relying solely on negotiation. The success of this act could also influence investment decisions in the pharmaceutical sector, encouraging more companies to enter the biosimilar space, which could lead to a more dynamic and cost-efficient drug market in the long run. It also underscores the ongoing challenge of translating legislative intent into effective, practical regulations.








